| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Represents the amount of increase decrease in costs related to settlements | NaN | 0 | 300,000 | NaN |
| Represents the amount of costs to issue debentures | NaN | 0 | 0 | 111,725 |
| Represents the amount of change in fair value of debentures | NaN | 0 | 383,823 | 200,000 |
| Repayment of debentures on extinguishment | NaN | 0 | -25,000 | NaN |
| Research and development expense (excluding acquired in process cost) | NaN | 0 | 8,717,475 | NaN |
| Net loss for the year | -9,042,311 | -8,184,557 | -27,259,804 | NaN |
| Foreign exchange gain/loss | NaN | -33,131 | -8,816 | NaN |
| Stock-based compensation expense | 599,306 | 429,712 | 852,757 | 229,725 |
| Increase (decrease) in accounts payable | NaN | NaN | NaN | 404,670 |
| Paid-in-kind interest | 379,254 | 339,381 | 89,680 | 0 |
| Represents the amount of operating lease right-of-use assets | 26,402 | 25,516 | 24,750 | 47,572 |
| Net income (loss) attributable to parent | NaN | NaN | NaN | -11,278,492 |
| Represents the amount of gain loss on settlements | -127,083 | -121,133 | -157,721 | NaN |
| Prepaid expenses | -169,351 | -35,303 | -430,723 | 113,201 |
| Deferred financing costs | NaN | 99,305 | 0 | 0 |
| Increase (decrease) in accounts payable, trade | -1,263,656 | 1,303,585 | -380,033 | NaN |
| Increase (decrease) in accounts payable and accrued liabilities | 44,650 | -549,969 | -954,308 | 1,065,475 |
| Increase (decrease) in operating lease liability | -40,514 | -36,441 | -50,058 | -56,113 |
| Increase (decrease) in accounts payable, related parties | 30,747 | -26,604 | 21,807 | -21,186 |
| Net cash used in operating activities | -8,969,688 | -6,609,115 | -6,757,829 | -9,409,825 |
| Proceeds from warrant exercises | NaN | 5,145,600 | 3,752,000 | 977,398 |
| Proceeds from issuance of debentures | NaN | 0 | 7,366,293 | 4,500,000 |
| Proceeds from convertible debt | NaN | 0 | 0 | 0 |
| Proceeds from issuance initial public offering | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock | 0 | 0 | 9,790,015 | NaN |
| Cash paid for financing costs in connection with sepa | -297,783 | NaN | NaN | 297,783 |
| Proceeds from stock options exercised | NaN | 0 | 162,400 | NaN |
| Repayment of new debenture | 3,184,908 | 1,753,398 | 5,637,709 | NaN |
| Represent the amount of proceeds from issuance of common shares and warrants | NaN | NaN | NaN | 9,790,015 |
| Costs to issue debentures | NaN | 0 | 136,726 | NaN |
| Represents the amount of proceeds from issuance of shares under settlements | 4,102,740 | 3,330,411 | 5,097,005 | NaN |
| Represents the amount of proceed from costs to issue debentures | NaN | NaN | NaN | -54,582 |
| Issuance costs for common shares | NaN | 69,143 | 584,361 | NaN |
| Represents the amount of proceeds from issuance of common stock at the market offering net of issuance costs | -5,907,319 | NaN | NaN | NaN |
| Net cash provided by financing activities | 6,825,151 | 6,653,470 | 10,371,267 | 14,915,048 |
| Represents the amount of net cash paid for antev asset acquisition including transaction costs | NaN | 0 | 4,619,152 | NaN |
| Cash provided by (used in) investing activity, including discontinued operation | NaN | 0 | -4,619,152 | NaN |
| Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | -195,057 | -1,228 | -1,741 | NaN |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation | -2,339,594 | 43,127 | 4,497,768 | NaN |
| Cash and cash equivalents, end of the period | 8,705,218 | 4,164,323 | 4,164,323 | NaN |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect | NaN | NaN | NaN | 5,505,223 |
| Cash and cash equivalents, end of the period | 6,365,624 | 8,705,218 | 8,662,091 | NaN |
Medicus Pharma Ltd. (MDCXW)
Medicus Pharma Ltd. (MDCXW)